– FRANCE, Paris – TISSIUM, a privately-owned MedTech company developing biomorphic programmable polymers for tissue reconstruction, today announced the appointment of Michel Thérin to its Board as Independent Director.
“We are pleased to have a new member as accomplished and reputable as Michel to join the board at TISSIUM at such a pivotal moment for the company. His experience and deep market knowledge, especially in the medical implant sector, will be valuable assets as we advance through the next stages of development.” said CEO, Christophe Bancel.
About Michel Thérin
Michel Thérin has had a long career as a global leader in the medical device industry, and he has extensive development, clinical, business, and strategic expertise in the field of Biosurgery and Minimally Invasive Surgery.
Mr. Thérin is the President of Advanced Therapies at Siemens Healthineers. He previously spent more than a decade at Medtronic in the Minimally Invasive Therapies Group where he served as the Global VP and General Manager of General Surgery, and in various roles working on research, development, and strategy. For nearly a decade before that, he was a General Manager and VP, Research & Development at Floreane Medical Implants that eventually was acquired by Covidien.
Mr. Thérin commented: “I am excited to have the opportunity to work alongside the accomplished innovators at TISSIUM. The Company’s efforts to provide solutions for patients in need of better tissue reconstruction is remarkable and stands to greatly impact the larger MedTech industry.”
He earned his Ph.D. in Biomedical Engineering and Biomaterials from Université Paris 13, his Doctorate in Veterinary Medicine from Maisons Alfort, and an Advanced Degree in Experimental & Toxicological Pathology at Université Pierre-et-Marie-Curie.
About TISSIUM
TISSIUM is a privately-owned MedTech company based in Paris, France that is dedicated to the rapid development and commercialization of a unique biopolymer platform to address various unmet clinical needs.
The company’s platform is based on a proprietary polymer family with unique properties including the ability to conform to and integrate with surrounding tissue to enable tissue reconstruction. Furthermore, the polymer building blocks enable customization to match tissue-specific requirements for different therapeutic areas. The company is developing a portfolio of solutions for peripheral nerve, gastrointestinal, ENT, and cardiovascular applications. The company also develops delivery and activation devices for enhanced performance and usability of its family of polymers.
TISSIUM’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013.
For more information: https://tissium.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.